Full metadata record

DC Field Value Language
dc.contributor.authorSon, Sohee-
dc.contributor.authorLim, Sung Mook-
dc.contributor.authorChae, Su Young-
dc.contributor.authorKim, Kwangmeyung-
dc.contributor.authorPark, Eun Ji-
dc.contributor.authorLee, Kang Choon-
dc.contributor.authorNa, Dong Hee-
dc.date.accessioned2024-01-20T05:33:58Z-
dc.date.available2024-01-20T05:33:58Z-
dc.date.created2022-01-25-
dc.date.issued2015-11-
dc.identifier.issn0378-5173-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/124780-
dc.description.abstractHydrophobically modified glycol chitosan (HGC) nanoparticles loaded with mono-lithocholic acid-conjugated exendin-4 at the Lys(27) residue (LAM1-Ex4) were prepared and characterized by particle size measurement, proteolytic stability, in vitro drug-release profile, and in vivo antidiabetic effects in a db/db diabetic mouse model. Compared with Ex-4-loaded HGC nanoparticles (Ex4/HGC NPs) prepared as a control, LAM1-Ex4-loaded HGC nanoparticles (LAM1-Ex4/HGC NPs) showed improved drug-loading efficiency, small particle size, enhanced resistance against proteolytic digestion, and an extended in vitro drug release profile. These findings may be attributable to the strong hydrophobic interaction between LAM1-Ex4 and the inner core of HGC. Furthermore, LAM1-Ex4/HGC NPs showed prolonged hypoglycemic efficacy in db/db mice, lasting 1 week after a single subcutaneous administration. The present study demonstrated that LAM1-Ex4/HGC NPs have considerable potential as a long-acting sustained-release antidiabetic system for type 2 diabetes. (C) 2015 Elsevier B.V. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER-
dc.titleMono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects-
dc.typeArticle-
dc.identifier.doi10.1016/j.ijpharm.2015.08.084-
dc.description.journalClass1-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF PHARMACEUTICS, v.495, no.1, pp.81 - 86-
dc.citation.titleINTERNATIONAL JOURNAL OF PHARMACEUTICS-
dc.citation.volume495-
dc.citation.number1-
dc.citation.startPage81-
dc.citation.endPage86-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000362970000010-
dc.identifier.scopusid2-s2.0-84940727466-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusPEGYLATED EXENDIN-4-
dc.subject.keywordPlusTYPE-2-
dc.subject.keywordPlusEXENATIDE-
dc.subject.keywordPlusSTABILITY-
dc.subject.keywordPlusDELIVERY-
dc.subject.keywordPlusRECEPTOR-
dc.subject.keywordPlusRELEASE-
dc.subject.keywordPlusWEIGHT-
dc.subject.keywordPlusANALOG-
dc.subject.keywordAuthorExendin-4-
dc.subject.keywordAuthorGlycol chitosan-
dc.subject.keywordAuthorNanoparticles-
dc.subject.keywordAuthorLithocholic acid-
dc.subject.keywordAuthorAntidiabetic effects-
Appears in Collections:
KIST Article > 2015
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE